FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3155013821> ?p ?o ?g. }

• W3155013821 endingPage "559" @default.
• W3155013821 startingPage "559" @default.
• W3155013821 abstract "P-glycoprotein (P-gp) inhibition has been studied to overcome multidrug resistance in cancer chemotherapy but failed in clinical trials due to low/toxic effects. Recently, a dual modulation of transporters and natural derivatives have been examined to surmount this limitation. We examined breast cancer resistance protein (BCRP) inhibition in vitro and in vivo by P-gp inhibitors derived from natural compounds in previous studies. P-gp inhibitors increased the accumulation of the anticancer drug, topotecan (TPT)—a substrate of P-gp and BCRP, albeit with higher affinity for BCRP—in BCRP-overexpressing cells, resulting in cell death. These dual inhibitors, when orally co-administered with TPT, enhanced TPT bioavailability with slightly reduced total oral clearance (Clt/F) in rats. In xenograft mice, they strengthened oral TPT-induced tumor reduction with no alterations in body weight. Moreover, we investigated the effects of an oral drug formulation (Cremophor® EL, Tween® 80, and polyethylene glycol 400) on the transporters function. The excipients increased TPT accumulation in P-gp- or BCRP-overexpressing cells. Oral TPT bioavailability was higher with the formulation than with a control, as shown by the increases in the maximum plasma concentration (Cmax) and the area under the plasma concentration–time curve from zero to infinity (AUCINF) (p< 0.01). Therefore, oral TPT bioavailability was enhanced by P-gp/BCRP dual inhibition, which resulted in a formulation-mediated increase in absorption and decrease in elimination, and a dual inhibitor-mediated decrease in elimination. These results suggest that the combination of dual inhibition by a natural derivative and the drug formulation can be a useful clinical approach." @default.
• W3155013821 created "2021-04-26" @default.
• W3155013821 creator A5001749842 @default.
• W3155013821 creator A5004108677 @default.
• W3155013821 creator A5013438369 @default.
• W3155013821 creator A5033468301 @default.
• W3155013821 creator A5036794371 @default.
• W3155013821 creator A5046281788 @default.
• W3155013821 creator A5047823882 @default.
• W3155013821 creator A5059715921 @default.
• W3155013821 creator A5072200429 @default.
• W3155013821 creator A5083179882 @default.
• W3155013821 creator A5083319953 @default.
• W3155013821 date "2021-04-15" @default.
• W3155013821 modified "2023-10-16" @default.
• W3155013821 title "Dual Inhibition of P-gp and BCRP Improves Oral Topotecan Bioavailability in Rodents" @default.
• W3155013821 cites W1997813700 @default.
• W3155013821 cites W2010427019 @default.
• W3155013821 cites W2012431429 @default.
• W3155013821 cites W2028533496 @default.
• W3155013821 cites W2052224385 @default.
• W3155013821 cites W2068442128 @default.
• W3155013821 cites W2070540557 @default.
• W3155013821 cites W2078690139 @default.
• W3155013821 cites W2092204069 @default.
• W3155013821 cites W2097161597 @default.
• W3155013821 cites W2101193630 @default.
• W3155013821 cites W2109689528 @default.
• W3155013821 cites W2119010359 @default.
• W3155013821 cites W2126307777 @default.
• W3155013821 cites W2142024216 @default.
• W3155013821 cites W2158838192 @default.
• W3155013821 cites W2174049160 @default.
• W3155013821 cites W2284964360 @default.
• W3155013821 cites W2512058578 @default.
• W3155013821 cites W2552657453 @default.
• W3155013821 cites W2560974557 @default.
• W3155013821 cites W2772034120 @default.
• W3155013821 cites W2779730509 @default.
• W3155013821 cites W2796552195 @default.
• W3155013821 cites W2805729137 @default.
• W3155013821 cites W2887030288 @default.
• W3155013821 cites W2909244384 @default.
• W3155013821 cites W2946182267 @default.
• W3155013821 cites W2983421574 @default.
• W3155013821 cites W2997377203 @default.
• W3155013821 cites W3002485806 @default.
• W3155013821 cites W3003960861 @default.
• W3155013821 cites W4210979734 @default.
• W3155013821 cites W4211244839 @default.
• W3155013821 cites W4235607015 @default.
• W3155013821 doi "https://doi.org/10.3390/pharmaceutics13040559" @default.
• W3155013821 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8071537" @default.
• W3155013821 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33921129" @default.
• W3155013821 hasPublicationYear "2021" @default.
• W3155013821 type Work @default.
• W3155013821 sameAs 3155013821 @default.
• W3155013821 citedByCount "12" @default.
• W3155013821 countsByYear W31550138212021 @default.
• W3155013821 countsByYear W31550138212022 @default.
• W3155013821 countsByYear W31550138212023 @default.
• W3155013821 crossrefType "journal-article" @default.
• W3155013821 hasAuthorship W3155013821A5001749842 @default.
• W3155013821 hasAuthorship W3155013821A5004108677 @default.
• W3155013821 hasAuthorship W3155013821A5013438369 @default.
• W3155013821 hasAuthorship W3155013821A5033468301 @default.
• W3155013821 hasAuthorship W3155013821A5036794371 @default.
• W3155013821 hasAuthorship W3155013821A5046281788 @default.
• W3155013821 hasAuthorship W3155013821A5047823882 @default.
• W3155013821 hasAuthorship W3155013821A5059715921 @default.
• W3155013821 hasAuthorship W3155013821A5072200429 @default.
• W3155013821 hasAuthorship W3155013821A5083179882 @default.
• W3155013821 hasAuthorship W3155013821A5083319953 @default.
• W3155013821 hasBestOaLocation W31550138211 @default.
• W3155013821 hasConcept C104317684 @default.
• W3155013821 hasConcept C112705442 @default.
• W3155013821 hasConcept C126322002 @default.
• W3155013821 hasConcept C133936738 @default.
• W3155013821 hasConcept C149011108 @default.
• W3155013821 hasConcept C150903083 @default.
• W3155013821 hasConcept C181389837 @default.
• W3155013821 hasConcept C185592680 @default.
• W3155013821 hasConcept C207001950 @default.
• W3155013821 hasConcept C22979827 @default.
• W3155013821 hasConcept C2776694085 @default.
• W3155013821 hasConcept C2777056448 @default.
• W3155013821 hasConcept C2778707650 @default.
• W3155013821 hasConcept C2781209748 @default.
• W3155013821 hasConcept C44312359 @default.
• W3155013821 hasConcept C501593827 @default.
• W3155013821 hasConcept C512196 @default.
• W3155013821 hasConcept C55493867 @default.
• W3155013821 hasConcept C71924100 @default.
• W3155013821 hasConcept C86803240 @default.
• W3155013821 hasConcept C98274493 @default.
• W3155013821 hasConceptScore W3155013821C104317684 @default.
• W3155013821 hasConceptScore W3155013821C112705442 @default.
• W3155013821 hasConceptScore W3155013821C126322002 @default.

• next